Analystreport

Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.

Corcept Therapeutics Incorporated  (CORT) 
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corcept.com/investors